Immunoprecipitation of human immunodeficiency virus type 2 glycoproteins by sera positive for human immunodeficiency virus type 1.
Analysis by radioimmunoprecipitation of serum samples from 27 different human immunodeficiency virus type 1 (HIV-1)-infected individuals residing in Chile showed that the sera of 26% of these individuals also react with glycoprotein gp125 of HIV type 2 (HIV-2). This cross-reaction seems to reflect a qualitative difference among infected individuals, because the titer of antibodies against gp120 of HIV-1 in the cross-reacting samples did not differ significantly from that in the non-cross-reacting samples. Most of the HIV-1-seropositive sera, including many that did not react with gp125 of HIV-2, reacted with gp140, the precursor of HIV-2 glycoproteins. The observed cross-reactions allowed us to distinguish three groups of HIV-1-infected individuals: (i) those whose sera react with both gp140 and gp125, (ii) those whose sera react with gp140, and (iii) those whose sera react with neither of these glycoproteins. The possible cause and significance of these differences is under study.
Espejo
R T
RT
Centro de Estudios Cientificos de Santiago, Chile.
Uribe
P
P
D003429:Cross Reactions; D015686:Gene Products, env / Q000276:immunology; D006023:Glycoproteins / Q000276:immunology / Q000302:isolation & purification; D015483:HIV Antibodies; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D011498:Protein Precursors / Q000276:immunology; D015531:Radioimmunoprecipitation Assay; D012191:Retroviridae Proteins / Q000276:immunology* / Q000302:isolation & purification; D054299:env Gene Products, Human Immunodeficiency Virus
D015686:Gene Products, env; D006023:Glycoproteins; D015483:HIV Antibodies; D011498:Protein Precursors; D012191:Retroviridae Proteins; D054299:env Gene Products, Human Immunodeficiency Virus; C066316:gp125 envelope protein, Human immunodeficiency virus 2; C066315:gp140 envelope protein, Human immunodeficiency virus 2